Based on our data as well as previous reports, we conclude that the antitumoral activity of fosaprepitant is, indeed, due to selective TACR1 inhibition, and that TACR1 expression as well as SRC phosphorylation in primary neuroblastoma samples may be predictive for fosaprepitant sensitivity. This evidence concerns the gene TACR1 and neuroblastoma.